Raloxifene

Grey

Brand Name(s):Evista

Indication:Primary prevention of osteoporotic fractures in postmenopausal women

Rationale:1

Considered:Oct-07

Review Date:Oct-20

Comments:
Raloxifene is not recommended as a treatment option for the primary prevention of osteoporotic fragility fractures in postmenopausal women.

NICE TA160
Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended January 2010) October 2008